Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 43

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 43
---
      |   — |     |                           |     2 |     |      |     — |
| Total*                            |     | $                           | 824 |     | $    | 717 |     | $                         | 1,464 |     | $    | 1,273 |
| Royalties by product:             |     |                             |     |     |      |     |     |                           |       |     |      |       |
| DARZALEX                          |     | $                           | 638 |     | $    | 538 |     | $                         | 1,088 |     | $    |   885 |
| Kesimpta                          |     |                             | 108 |     |      |  80 |     |                           |   198 |     |      |   144 |
| TEPEZZA                           |     |                             |  20 |     |      |  23 |     |                           |    45 |     |      |    49 |

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 35/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
| Other** |     |   |  23 |     |   |  18 |     |   |    47 |     |   |    33 |
|:--------|:----|:--|----:|:----|:--|----:|:----|:--|------:|:----|:--|------:|
| Total   |     | $ | 789 |     | $ | 659 |     | $ | 1,378 |     | $ | 1,111 |

* Excludes Genmab’s Net product sales

** Other consist of royalties from net sales of RYBREVANT, TECVAYLI, TALVEY and TEPKINLY.

Net Product Sales

Genmab recognized net product sales of $ 176million during the first six months of 2025 compared to $ 109million in the first six months of 2024. EPKINLY was approved in the U.S. in May 2023 and Japan in September